{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:16:01Z","timestamp":1783350961010,"version":"3.54.6"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.clinthera.2024.12.007","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T13:37:29Z","timestamp":1735825049000},"page":"196-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of Effects on 6-Thioguanine Nucleotides According to Mesalazine Formulation in Pediatric Patients with Ulcerative Colitis"],"prefix":"10.1016","volume":"47","author":[{"given":"Hansol","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Zi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seon Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yon Ho","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4505-4083","authenticated-orcid":false,"given":"Mi Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clinthera.2024.12.007_bib0001","doi-asserted-by":"crossref","first-page":"135","DOI":"10.7861\/clinmed.2021-0080","article-title":"Ulcerative colitis: an update","volume":"21","author":"Segal","year":"2021","journal-title":"Clin Med (Lond)"},{"issue":"4","key":"10.1016\/j.clinthera.2024.12.007_bib0002","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2021.12.282","article-title":"Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review","volume":"162","author":"Kuenzig","year":"2022","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.clinthera.2024.12.007_bib0003","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00384-023-04417-6","article-title":"Trends in the prevalence and incidence of ulcerative colitis in Japan and the US","volume":"38","author":"Yamazaki","year":"2023","journal-title":"Int J Colorectal Dis"},{"issue":"2","key":"10.1016\/j.clinthera.2024.12.007_bib0004","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","article-title":"Understanding and preventing the global increase of inflammatory bowel disease","volume":"152","author":"Kaplan","year":"2017","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.clinthera.2024.12.007_bib0005","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MPG.0000000000002035","article-title":"Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and colitis organization and European society of paediatric gastroenterology, hepatology and nutrition","volume":"67","author":"Turner","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"8","key":"10.1016\/j.clinthera.2024.12.007_bib0006","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1084\/jem.20041948","article-title":"Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma","volume":"201","author":"Rousseaux","year":"2005","journal-title":"J Exp Med"},{"issue":"9","key":"10.1016\/j.clinthera.2024.12.007_bib0007","first-page":"2031","article-title":"Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews","volume":"19","author":"Feagan","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.clinthera.2024.12.007_bib0008","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4292\/wjgpt.v6.i4.137","article-title":"Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?","volume":"6","author":"Ye","year":"2015","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.clinthera.2024.12.007_bib0009","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/ibd.21193","article-title":"Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study","volume":"16","author":"Ito","year":"2010","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.clinthera.2024.12.007_bib0010","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0016-5085(82)80075-9","article-title":"5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans","volume":"83","author":"Rasmussen","year":"1982","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.clinthera.2024.12.007_bib0011","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2165\/00003495-200868080-00006","article-title":"Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes","volume":"68","author":"Fernandez-Becker","year":"2008","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.clinthera.2024.12.007_bib0012","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/BF02849976","article-title":"Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system","volume":"24","author":"Tenjarla","year":"2007","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.clinthera.2024.12.007_bib0013","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2036.2003.01445.x","article-title":"Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation","volume":"17","author":"Brunner","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2024.12.007_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102232","article-title":"Safety and efficacy of multimatrix mesalamine in paediatric patients with mild-to-moderate ulcerative colitis: a phase 3, randomised, double-blind study","volume":"65","author":"Croft","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.clinthera.2024.12.007_bib0015","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2147\/DDDT.S95316","article-title":"Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis","volume":"10","author":"Cuffari","year":"2016","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"10.1016\/j.clinthera.2024.12.007_bib0016","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2036.2009.04023.x","article-title":"Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis","volume":"30","author":"Gisbert","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"3-4","key":"10.1016\/j.clinthera.2024.12.007_bib0017","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000140974","article-title":"Efficacy and safety of azathioprine and 6-mercaptopurine in Japanese pediatric patients with ulcerative colitis: a survey of the Japanese Society for Pediatric Inflammatory Bowel Disease","volume":"77","author":"Tajiri","year":"2008","journal-title":"Digestion"},{"issue":"5","key":"10.1016\/j.clinthera.2024.12.007_bib0018","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0022-3476(05)83349-9","article-title":"Azathioprine in the treatment of children with inflammatory bowel disease","volume":"117","author":"Verhave","year":"1990","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.clinthera.2024.12.007_bib0019","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/01.MIB.0000206544.05661.9f","article-title":"5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine","volume":"12","author":"Hande","year":"2006","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.clinthera.2024.12.007_bib0020","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/gut.49.5.656","article-title":"Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide","volume":"49","author":"Lowry","year":"2001","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.clinthera.2024.12.007_bib0021","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2036.2002.01156.x","article-title":"Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease","volume":"16","author":"Dewit","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.clinthera.2024.12.007_bib0022","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1111\/jgh.15411","article-title":"Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S-methyltransferase inhibition","volume":"36","author":"Morikubo","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.clinthera.2024.12.007_bib0023","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/MPG.0000000000000239","article-title":"ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents","volume":"58","author":"Levine","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10.1016\/j.clinthera.2024.12.007_bib0024","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.gastro.2007.05.029","article-title":"Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study","volume":"133","author":"Turner","year":"2007","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.clinthera.2024.12.007_bib0025","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.clinthera.2024.12.007_bib0026","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/gast.2002.32420","article-title":"6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease","volume":"122","author":"Dubinsky","year":"2002","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.clinthera.2024.12.007_bib0027","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S1542-3565(05)00697-X","article-title":"6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease","volume":"3","author":"Neurath","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.clinthera.2024.12.007_bib0028","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1111\/j.1572-0241.2007.01511.x","article-title":"Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism","volume":"102","author":"de Boer","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.clinthera.2024.12.007_bib0029","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1476-5381.2010.00731.x","article-title":"Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy","volume":"160","author":"de Graaf","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.clinthera.2024.12.007_bib0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5217\/ir.2020.00155","article-title":"Use of thiopurines in inflammatory bowel disease: an update","volume":"20","author":"Singh","year":"2022","journal-title":"Intest Res"},{"issue":"5","key":"10.1016\/j.clinthera.2024.12.007_bib0031","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2036.2008.03915.x","article-title":"Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes?","volume":"29","author":"Andrews","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.clinthera.2024.12.007_bib0032","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2125.1995.tb04478.x","article-title":"Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine","volume":"39","author":"Szumlanski","year":"1995","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.clinthera.2024.12.007_bib0033","first-page":"919","article-title":"Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis","volume":"3","author":"Kedia","year":"2007","journal-title":"Ther Clin Risk Manag"},{"issue":"9","key":"10.1016\/j.clinthera.2024.12.007_bib0034","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1365-2036.2009.04117.x","article-title":"Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol","volume":"30","author":"Prantera","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.clinthera.2024.12.007_bib0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF02220605","article-title":"The clinical pharmacology of 6-mercaptopurine","volume":"43","author":"Lennard","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.clinthera.2024.12.007_bib0036","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/MIB.0000000000000347","article-title":"Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine","volume":"21","author":"Lee","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"10.1016\/j.clinthera.2024.12.007_bib0037","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1365-2036.2005.02460.x","article-title":"Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease","volume":"21","author":"Xin","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.clinthera.2024.12.007_bib0038","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update","volume":"105","author":"Relling","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.clinthera.2024.12.007_bib0039","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/ng.3060","article-title":"A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia","volume":"46","author":"Yang","year":"2014","journal-title":"Nat Genet"},{"issue":"18","key":"10.1016\/j.clinthera.2024.12.007_bib0040","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1158\/0008-5472.CAN-16-0584","article-title":"NUDT15 Hydrolyzes 6-Thio-DeoxyGTP to Mediate the Anticancer Efficacy of 6-Thioguanine","volume":"76","author":"Valerie","year":"2016","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.clinthera.2024.12.007_bib0041","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/s41467-017-01642-w","article-title":"A comprehensive structural, biochemical and biological profiling of the human NUDIX hydrolase family","volume":"8","author":"Carreras-Puigvert","year":"2017","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.clinthera.2024.12.007_bib0042","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4166\/kjg.2015.65.5.291","article-title":"[The frequency and the course of the adverse effects of azathioprine\/6-mercaptopurine treatment in patients with inflammatory bowel disease]","volume":"51","author":"Kim","year":"2008","journal-title":"Korean J Gastroenterol"},{"issue":"10","key":"10.1016\/j.clinthera.2024.12.007_bib0043","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1097\/MCG.0b013e3181d6baf5","article-title":"Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study","volume":"44","author":"Kim","year":"2010","journal-title":"J Clin Gastroenterol"},{"issue":"12","key":"10.1016\/j.clinthera.2024.12.007_bib0044","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1111\/j.1572-0241.2006.00843.x","article-title":"Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients","volume":"101","author":"Gisbert","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.clinthera.2024.12.007_bib0045","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1097\/MIB.0000000000000570","article-title":"Impact of genetic polymorphisms on 6-thioguanine nucleotide levels and toxicity in pediatric patients with IBD Treated with azathioprine","volume":"21","author":"Lee","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.clinthera.2024.12.007_bib0046","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/clpt.2010.320","article-title":"Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing","volume":"89","author":"Relling","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.clinthera.2024.12.007_bib0047","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/FPC.0000000000000274","article-title":"NUDT15 genotype distributions in the Korean population","volume":"27","author":"Kim","year":"2017","journal-title":"Pharmacogenet Genomics"},{"issue":"8","key":"10.1016\/j.clinthera.2024.12.007_bib0048","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jama.2019.0709","article-title":"Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease","volume":"321","author":"Walker","year":"2019","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.clinthera.2024.12.007_bib0049","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00535-018-1486-7","article-title":"NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study","volume":"53","author":"Kakuta","year":"2018","journal-title":"J Gastroenterol"},{"issue":"1","key":"10.1016\/j.clinthera.2024.12.007_bib0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5217\/ir.2017.15.1.7","article-title":"Second Korean guidelines for the management of ulcerative colitis","volume":"15","author":"Choi","year":"2017","journal-title":"Intest Res"},{"issue":"19","key":"10.1016\/j.clinthera.2024.12.007_bib0051","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2169\/internalmedicine.47.1268","article-title":"Analysis of thiopurine S-methyltransferase genotypes in Japanese patients with inflammatory bowel disease","volume":"47","author":"Ban","year":"2008","journal-title":"Intern Med"},{"issue":"7","key":"10.1016\/j.clinthera.2024.12.007_bib0052","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1440-1746.2009.05917.x","article-title":"Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease","volume":"24","author":"Takatsu","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.clinthera.2024.12.007_bib0053","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/FTD.0b013e3182731925","article-title":"Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?","volume":"34","author":"Fangbin","year":"2012","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.clinthera.2024.12.007_bib0054","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/apt.15810","article-title":"Adjustment of azathioprine dose should be based on a lower 6-TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers","volume":"52","author":"Kang","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.clinthera.2024.12.007_bib0055","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/MIB.0000000000000197","article-title":"Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD","volume":"21","author":"Amin","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.clinthera.2024.12.007_bib0056","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1517\/14740338.6.2.99","article-title":"The risks and the benefits of mesalazine as a treatment for ulcerative colitis","volume":"6","author":"Moss","year":"2007","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"10.1016\/j.clinthera.2024.12.007_bib0057","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/apt.14688","article-title":"Systematic review: safety of mesalazine in ulcerative colitis","volume":"47","author":"Sehgal","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.clinthera.2024.12.007_bib0058","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1515\/CCLM.2008.187","article-title":"Thiopurine S-methyltransferase (TPMT) pharmacogenetics: three new mutations and haplotype analysis in the Estonian population","volume":"46","author":"Tamm","year":"2008","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"10.1016\/j.clinthera.2024.12.007_bib0059","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00228-004-0732-5","article-title":"Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age","volume":"60","author":"Ganiere-Monteil","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"issue":"1-2","key":"10.1016\/j.clinthera.2024.12.007_bib0060","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.cca.2008.08.014","article-title":"Duplex pyrosequencing of the TPMT*3C and TPMT*6 alleles in Korean and Vietnamese populations","volume":"398","author":"Lee","year":"2008","journal-title":"Clin Chim Acta"},{"issue":"3","key":"10.1016\/j.clinthera.2024.12.007_bib0061","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/FPC.0000000000000117","article-title":"Complete sequence-based screening of TPMT variants in the Korean population","volume":"25","author":"Kim","year":"2015","journal-title":"Pharmacogenet Genomics"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824004119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824004119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:30:07Z","timestamp":1740529807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824004119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0149291824004119"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.12.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Effects on 6-Thioguanine Nucleotides According to Mesalazine Formulation in Pediatric Patients with Ulcerative Colitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}